Actinogen is pleased to announce the early closure of blood pTau screening in the XanaMIA Alzheimer's trial on October 31, due to strong recruitment. With 180 participants currently enrolled, ~240 participants in total are projected by year-end. An interim analysis will occur late January 2026 and final results are now projected for mid Q4 2026. The trial's recent accelerated enrollment is consistent with positive market research findings on the attactiveness of oral Xanamem compared with other AD therapies.